19 minute listen time
9 September 2021
Subscribe to Talking Property with CBRE

APPLE_button_165x40
SPOTIFY_button_165x40

 

The life science industry is expected to be a major growth sector in Australia over the coming years with global pharmaceutical companies expanding their production capabilities across R&D, manufacturing, and distribution. This expansion, backed by Federal Government support is set to solidify Australia’s sovereign capability as the COVID-19 pandemic prompts a greater focus on this sector. So how will this impact occupier and investment activity growth within commercial property and where do we see this sector in ten years? 

In this episode of Talking Property, Sass J-Baleh Head of Industrial & Logistics Research at CBRE sits down with Julie Phillips, CEO and Director of BioDiem, Jack Walters Head of Industrial Transactions at Charter Hall and Chris O’Brien Executive Director, Capital Markets, Industrial & Logistics at CBRE. Together, they take a closer a look at the Australian life sciences sector from pharmaceutical manufacturing and demand for life science assets, through to the types of investor groups showing interest, major transactions and their predictions for industry growth over the next decade.

VIEW THE AUSTRALIAN LIFE SCIENCES REPORT


 

Featuring


Julie Phillips – CEO & Director, BioDiem Ltd

Julie is CEO and Director of BioDiem Ltd and its subsidiary, Opal Biosciences Ltd. She chairs the federal government's R&D Incentives Committee. She is a non-executive director of the Medtech and Pharma Growth Centre, MTP Connect. Throughout her career in the biotech industry, she has also held positions such as Chair of AusBiotech Ltd, Australia’s peak biotechnology industry association.

VIEW PROFILE


 Jack Walters – Head of Industrial Transactions, Charter Hall

Jack is responsible for leading the Charter Hall Capital Transactions team across industrial acquisitions nationally. Prior to this, Jack was an executive in the Wholesale Retail Business within Charter Hall responsible for ~$4.5bn of funds under management across six funds/partnerships.

VIEW PROFILE


Chris O’Brien - Executive Director, Capital Markets, Industrial & Logistics, APAC, CBRE

Chris is the Executive Director of CBRE’S Industrial & Logistics, Capital Markets division, specialising in servicing an extensive offshore and domestic client base. He previously held the role of Head of Australia's Industrial Valuations & Advisory Services, thus provides vast experience in various asset classes throughout Australia.

VIEW PROFILE


 Sass J-Baleh – Head of Industrial & Logistics Research Pacific & Director of NSW Research Australia, CBRE

Sass is the Head of Industrial and Logistics Research in Australia at CBRE and leads the NSW Research platform across all sectors. She provides high quality research advice to internal business lines, as well as clients of the organisation - particularly to executive level decision-makers.  She participates in a number of initiatives, including economic and market analyses, forecasting, research client engagement, report, product and data development..

VIEW PROFILE


More on Life Sciences from CBRE Research

AUSTRALIA: A New Era of Growth in Life Sciences

This report provides an overview of Australia’s life science real estate, focusing on key trends, demand drivers and investment opportunities in major life science hubs.

Episode 25: A New Era of Life Sciences Growth

Asia Pacific is home to approximately 60% of the global population. The region includes the many of the world’s most populous and fastest-growing countries. This report looks the driving forces behind the Life Sciences sector in Asia Pacific.

An Australian Whitecoat Whitepaper

Australia’s tertiary institutions remain critical to Australia’s infrastructure and a key piece of the life sciences puzzle which has been rapidly emerging sector in recent year.